<DOC>
	<DOC>NCT01012973</DOC>
	<brief_summary>To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Centerinvolved macular edema secondary to central retinal vein occlusion (CRVO) for no longer than 9 months with mean central subfield thickness ≥ 250 μm on optical coherence tomography (OCT) Adults ≥ 18 years Early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters) in the study eye Any prior treatment with antiVEGF agents in the study eye (Pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc.) or previous administration of systemic antiangiogenic medications Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye CRVO disease duration &gt; 9 months from date of diagnosis Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1 Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Macular Edema</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
	<keyword>CRVO</keyword>
	<keyword>VEGF Trap-Eye</keyword>
	<keyword>best-corrected visual acuity</keyword>
</DOC>